Marcus Vetter
Head of Department
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Marcus Vetter is an Assistant Professor at University Hospital Basel in Switzerland. His research primarily focuses on oncology, particularly in the areas of metastatic breast cancer treatment, machine learning applications in patient-reported outcomes, and the management of cancer therapy-related side effects. His recent publications reflect a commitment to improving personalized treatment approaches and understanding the prognostic factors in breast cancer and gynecological cancers.
Articles (22)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
In patients with hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2−) negative breast cancer (BC), the TAILORx study showed the benefit of adding chemotherapy (CHT) to endocrine therapy (ET) in a subgroup of patients under 50 years with an intermediate Oncotype DX recurrence score (RS 11–25). The aim of the present study was to determine if the TAILORx findings, including the changes in the RS categories, impacted CHT use in the intermediate RS (11–25) group in daily practice, as well as to identify the main factors for CHT decisions. We conducted a retrospective study on 326 BC patients (59% node-negative), of which 165 had a BC diagnosis before TAILORx (Cohort A) and 161 after TAILORx publication (Cohort B). Changes in the RS categories led to shifts in patient population distribution, thereby leading to a 40% drop in the low RS (from 60% to 20%), which represented a doubling in the intermediate RS (from 30% to 60%) and an increase of 5% in the high RS (from 8–10% to 15%). The overall CHT recommendation and application did not differ significantly between cohort B when compared with A (19% vs. 22%, resp., p = 0.763). In the intermediate RS (11–25), CHT use decreased by 5%, while in the high-risk RS category (>25), there was an increase of 13%. The tumor board recommended CHT for 90% of the patients according to the new RS guidelines in cohort A and for 85% in cohort B. The decision for CHT recommendation was based on age (OR 0.93, 95% CI 0.08–0.97, p = 0.001), nodal stage (OR 4.77, 95% CI 2.03–11.22, p < 0.001), and RS categories (RS 11–25 vs. RS 0–10: OR 0.06 (95% CI 0.02–0.17), p < 0.001; RS > 26 vs. RS 11–25: OR 618.18 95% CI 91.64–4169.91, p < 0.001), but did not depend on the cohort. In conclusion, while the tumor board recommendation for CHT decreased in the intermediate RS category, there was an increase being reported in the high RS category, thus leading to overall minor changes in CHT application. As expected, among the younger women with intermediate RS and unfavorable histopathological factors, CHT use increased.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (20)
Andreas Mueller
Dr. med.; Head of Breast Center
-
Céline Montavon
-
Céline Bolliger
University of Lucerne
Michael Krauthammer
Professor
University of Zurich
Markus Felix Templin
Natural and Medical Sciences Institute
Cvetka Grašič Kuhar
-
Ralf Kühn
Max Delbrück Centrum für Molekulare Medizin Berlin Buch
Kathrin Scherer
University of Basel
Francesc Castro-Giner
Head of Computational Biology
ETH Zürich
Kirsten Mertz
Head of Institute
University Hospital Basel
Walter Paul Weber
Co-leader
University Hospital Basel
Aleksandra Strojna
Kliniken Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH Klinik für Gynäkologie & Gynäkologische Onkologie
Seyed Mohsen Mousavi
Head
-
Gaetana Restivo
University of Zurich
Michael Linnebacher
Research Leader
Rostock University Medical Center
Gad Singer
Head of the Institute
-
Salvatore Piscuoglio
Associate Professor
Humanitas University
Mohamed Bentires-Alj
Professor of experimental surgical oncology
University of Basel
Zoia Razumova
Karolinska Institutet
Viola Heinzelmann-Schwarz
University Hospital Basel
Make your next move.
Prepare your application
Review drafts before you send them.